{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T10:47:36Z","timestamp":1785840456310,"version":"3.56.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007051","name":"Uppsala University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007051","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Hepatocellular carcinoma (HCC) is the most frequent type of primary liver cancer and is often diagnosed at an intermediate stage in patients with chronic liver disease. Transarterial chemoembolization (TACE) is the first-line treatment in this setting. However, drug response remains variable and optimal chemotherapeutic selection unresolved. Idarubicin (IDA) has previously demonstrated antitumor activity comparable to doxorubicin (DOX), with improved emulsion stability and membrane permeability. 3D patient-derived organoids (PDOs) have also recently emerged as physiologically relevant systems that recapitulate tumor characteristics and inter-patient heterogeneity more accurately than conventional 2D cell cultures. In this study, we characterized HCC PDOs and investigated their utility as an ex vivo model to assess therapeutic responses. We generated organoids from tumor and non-tumor liver biopsies collected from HCC patients prior to TACE-treatment. PDOs partially preserved tumor architecture and phenotypic features. IDA exposure resulted in a concentration-dependent reduction in organoid growth, with marked inter-patient variability in drug response. Comparative analyses showed that IDA was more potent than DOX, with lower IC\u2085\u2080 values across all patient-derived samples. IDA also induced transcriptional changes associated with cellular stress, inflammation, and proliferation pathways. However, ex vivo drug\u2011sensitivity testing in PDOs did not correlate with clinical response to TACE. These findings confirm the feasibility of generating HCC PDOs and using them to evaluate differential sensitivity to TACE\u2011associated chemotherapeutic agents ex vivo, although their ability to predict clinical efficacy remains unproven. While IDA exhibited greater cytotoxic activity than DOX in organoid cultures, this observation was based on in vitro sensitivity assays and does not establish clinical superiority. Furthermore, the absence of correlation between PDO drug sensitivity and clinical TACE response indicates that PDO-based prediction of treatment outcome remains challenging in this setting.<\/jats:p>","DOI":"10.1038\/s41598-026-65418-3","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T08:04:56Z","timestamp":1785830696000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Characterization of hepatocellular carcinoma patient-derived organoids from patients receiving transarterial chemoembolization as a model for preclinical drug response assessment"],"prefix":"10.1038","volume":"16","author":[{"given":"Jaafar","family":"Khaled","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofi Sennefelt","family":"Nyman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Dahlgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Rorsman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Lennern\u00e4s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte Ebeling","family":"Barbier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Femke","family":"Heindryckx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"key":"65418_CR1","doi-asserted-by":"publisher","first-page":"p158","DOI":"10.1002\/hep.31327","volume":"73 Suppl 1","author":"JM Llovet","year":"2021","unstructured":"Llovet, J. M. et al. Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference. Hepatology 73 Suppl 1, p158\u2013191 (2021).","journal-title":"Hepatology"},{"issue":"12","key":"65418_CR2","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/s41571-023-00825-3","volume":"20","author":"AG Singal","year":"2023","unstructured":"Singal, A. G., Kanwal, F. & Llovet, J. M. Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy. Nat. Reviews Clin. Oncol. 20 (12), 864\u2013884 (2023).","journal-title":"Nat. Reviews Clin. Oncol."},{"issue":"2","key":"65418_CR3","doi-asserted-by":"publisher","first-page":"165","DOI":"10.4254\/wjh.v7.i2.165","volume":"7","author":"F Heindryckx","year":"2015","unstructured":"Heindryckx, F. & Gerwins, P. Targeting the tumor stroma in hepatocellular carcinoma. World J. Hepatol. 7 (2), 165\u2013176 (2015).","journal-title":"World J. Hepatol."},{"issue":"3","key":"65418_CR4","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.cnc.2022.04.004","volume":"34","author":"H Gilles","year":"2022","unstructured":"Gilles, H., Garbutt, T. & Landrum, J. Hepatocellular Carcinoma. Crit. Care Nurs. Clin. North. Am. 34 (3), 289\u2013301 (2022).","journal-title":"Crit. Care Nurs. Clin. North. Am."},{"issue":"6","key":"65418_CR5","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J. Clin. 68 (6), 394\u2013424 (2018).","journal-title":"Cancer J. Clin."},{"key":"65418_CR6","doi-asserted-by":"crossref","unstructured":"Ebeling Barbier, C., Heindryckx, F. & Lennernas, H. Limitations and Possibilities of Transarterial Chemotherapeutic Treatment of Hepatocellular Carcinoma. Int. J. Mol. Sci., 22(23). (2021).","DOI":"10.3390\/ijms222313051"},{"key":"65418_CR7","doi-asserted-by":"publisher","first-page":"715","DOI":"10.2147\/CMAR.S156837","volume":"10","author":"W Guo","year":"2018","unstructured":"Guo, W. et al. Deciphering hepatocellular carcinoma through metabolomics: from biomarker discovery to therapy evaluation. Cancer Manag Res. 10, 715\u2013734 (2018).","journal-title":"Cancer Manag Res."},{"issue":"10","key":"65418_CR8","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.4254\/wjh.v7.i10.1412","volume":"7","author":"KW Chen","year":"2015","unstructured":"Chen, K. W. et al. Current systemic treatment of hepatocellular carcinoma: A review of the literature. World J. Hepatol. 7 (10), 1412\u20131420 (2015).","journal-title":"World J. Hepatol."},{"issue":"6","key":"65418_CR9","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1111\/bcpt.13790","volume":"131","author":"D Dahlgren","year":"2022","unstructured":"Dahlgren, D. et al. Evaluation and validation of chemotherapy-specific diarrhoea and histopathology in rats. Basic. Clin. Pharmacol. Toxicol. 131 (6), 536\u2013546 (2022).","journal-title":"Basic. Clin. Pharmacol. Toxicol."},{"issue":"6","key":"65418_CR10","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1111\/bcpt.13851","volume":"132","author":"F Kullenberg","year":"2023","unstructured":"Kullenberg, F. et al. Anakinra and dexamethasone treatment of idarubicin-induced mucositis and diarrhoea in rats. Basic. Clin. Pharmacol. Toxicol. 132 (6), 511\u2013520 (2023).","journal-title":"Basic. Clin. Pharmacol. Toxicol."},{"issue":"1","key":"65418_CR11","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/hep.28453","volume":"64","author":"R Lencioni","year":"2016","unstructured":"Lencioni, R. et al. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data. Hepatology 64 (1), 106\u2013116 (2016).","journal-title":"Hepatology"},{"issue":"3","key":"65418_CR12","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1007\/s00270-023-03621-9","volume":"47","author":"JW Choi","year":"2024","unstructured":"Choi, J. W. et al. Transarterial Chemoembolization Using Idarubicin Versus Doxorubicin Chemoemulsion in Patients with Hepatocellular Carcinoma (IDADOX): Protocol for a Randomized, Non-inferiority, Double-Blind Trial. Cardiovasc. Interv. Radiol. 47 (3), 372\u2013378 (2024).","journal-title":"Cardiovasc. Interv. Radiol."},{"key":"65418_CR13","doi-asserted-by":"crossref","unstructured":"Favelier, S. et al. Lipiodol Trans-arterial Chemoembolization of Hepatocellular Carcinoma with Idarubicin: First Experience 36 (Cardiovascular and interventional radiology, 2012).","DOI":"10.1007\/s00270-012-0532-8"},{"issue":"3","key":"65418_CR14","doi-asserted-by":"publisher","first-page":"324","DOI":"10.3748\/wjg.v26.i3.324","volume":"26","author":"GS Roth","year":"2020","unstructured":"Roth, G. S. et al. Idarubicin vs doxorubicin in transarterial chemoembolization of intermediate stage hepatocellular carcinoma. World J. Gastroenterol. 26 (3), 324\u2013334 (2020).","journal-title":"World J. Gastroenterol."},{"issue":"8","key":"65418_CR15","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1097\/CAD.0b013e328346a0c5","volume":"22","author":"M Boulin","year":"2011","unstructured":"Boulin, M. et al. Screening of anticancer drugs for chemoembolization of hepatocellular carcinoma. Anticancer Drugs. 22 (8), 741\u2013748 (2011).","journal-title":"Anticancer Drugs"},{"key":"65418_CR16","doi-asserted-by":"publisher","first-page":"118859","DOI":"10.1016\/j.biopha.2025.118859","volume":"193","author":"A Lerma-Clavero","year":"2025","unstructured":"Lerma-Clavero, A. et al. A comparative study of idarubicin and doxorubicin in a chemically-induced in vivo mouse model for hepatocellular carcinoma. Biomed. Pharmacother. 193, 118859 (2025).","journal-title":"Biomed. Pharmacother"},{"issue":"2","key":"65418_CR17","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s00330-015-3855-4","volume":"26","author":"M Boulin","year":"2016","unstructured":"Boulin, M. et al. Improved stability of lipiodol\u2013drug emulsion for transarterial chemoembolisation of hepatocellular carcinoma results in improved pharmacokinetic profile: Proof of concept using idarubicin. Eur. Radiol. 26 (2), 601\u2013609 (2016).","journal-title":"Eur. Radiol."},{"issue":"3","key":"65418_CR18","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1148\/radiol.2019190789","volume":"291","author":"SA Padia","year":"2019","unstructured":"Padia, S. A. Is Idarubicin the Future of TACE? Radiology 291 (3), 809\u2013810 (2019).","journal-title":"Radiology"},{"issue":"5","key":"65418_CR19","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/j.celrep.2018.07.001","volume":"24","author":"S Nuciforo","year":"2018","unstructured":"Nuciforo, S. et al. Organoid Models of Human Liver Cancers Derived from Tumor Needle Biopsies. Cell. Rep. 24 (5), 1363\u20131376 (2018).","journal-title":"Cell. Rep."},{"issue":"1","key":"65418_CR20","doi-asserted-by":"publisher","first-page":"p19506","DOI":"10.1038\/s41598-025-03504-8","volume":"15","author":"P Guerrero-Lopez","year":"2025","unstructured":"Guerrero-Lopez, P. et al. 2D versus 3D tumor-on-chip models to study the impact of tumor organization on metabolic patterns in vitro. Sci. Rep. 15 (1), p19506 (2025).","journal-title":"Sci. Rep."},{"key":"65418_CR21","doi-asserted-by":"crossref","unstructured":"Verduin, M. et al. Patient-Derived Cancer Organoids as Predictors of Treatment Response. Front. Oncol., 11. (2021).","DOI":"10.3389\/fonc.2021.641980"},{"issue":"6378","key":"65418_CR22","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1126\/science.aao2774","volume":"359","author":"G Vlachogiannis","year":"2018","unstructured":"Vlachogiannis, G. et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science 359 (6378), 920\u2013926 (2018).","journal-title":"Science"},{"key":"65418_CR23","doi-asserted-by":"crossref","unstructured":"Doelvers, F. et al. Impact of culture dimensionality and matrix composition on morphology, phenotype and drug response in pancreatic cancer models. Sci. Rep., 16(1). (2026).","DOI":"10.1038\/s41598-026-47856-1"},{"key":"65418_CR24","doi-asserted-by":"crossref","unstructured":"Walaas, G. A. E. et al. Patient-matched transcriptomics of in vivo and in vitro colonic epithelium substantiate organoids as a translational model for ulcerative colitis. Sci. Rep., (2026).","DOI":"10.1038\/s41598-026-54857-7"},{"issue":"11","key":"65418_CR25","doi-asserted-by":"publisher","first-page":"e065839","DOI":"10.1136\/bmjopen-2022-065839","volume":"12","author":"SS Nyman","year":"2022","unstructured":"Nyman, S. S. et al. Study protocol for locoregional precision treatment of hepatocellular carcinoma with transarterial chemoembolisation (TACTida), a clinical study: idarubicin dose selection, tissue response and survival. BMJ Open. 12 (11), e065839 (2022).","journal-title":"BMJ Open."},{"issue":"15","key":"65418_CR26","doi-asserted-by":"publisher","first-page":"6235","DOI":"10.1073\/pnas.1015938108","volume":"108","author":"J Kondo","year":"2011","unstructured":"Kondo, J. et al. Retaining cell-cell contact enables preparation and culture of spheroids composed of pure primary cancer cells from colorectal cancer. Proc. Natl. Acad. Sci. U S A. 108 (15), 6235\u20136240 (2011).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"65418_CR27","unstructured":"Bancroft, J. D. & Gamble, M. Theory and Practice of Histological Techniques 7th edn (Churchill Livingstone, 2013)."},{"issue":"6","key":"65418_CR28","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1101\/pdb.prot073411","volume":"2014","author":"RD Cardiff","year":"2014","unstructured":"Cardiff, R. D., Miller, C. H. & Munn, R. J. Manual hematoxylin and eosin staining of mouse tissue sections. Cold Spring Harb Protoc. 2014 (6), 655\u2013658 (2014).","journal-title":"Cold Spring Harb Protoc."},{"key":"65418_CR29","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.humpath.2020.12.009","volume":"112","author":"MS Torbenson","year":"2021","unstructured":"Torbenson, M. S. Hepatocellular carcinoma: making sense of morphological heterogeneity, growth patterns, and subtypes. Hum. Pathol. 112, 86\u2013101 (2021).","journal-title":"Hum. Pathol."},{"issue":"2","key":"65418_CR30","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1021\/acs.molpharmaceut.6b00886","volume":"14","author":"E Lilienberg","year":"2017","unstructured":"Lilienberg, E. et al. Vivo Drug Delivery Performance of Lipiodol-Based Emulsion or Drug-Eluting Beads in Patients with Hepatocellular Carcinoma. Mol. Pharm. 14 (2), 448\u2013458 (2017).","journal-title":"Mol. Pharm."},{"issue":"6","key":"65418_CR31","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1016\/j.jhep.2011.03.024","volume":"55","author":"J Namur","year":"2011","unstructured":"Namur, J. et al. Embolization of hepatocellular carcinoma with drug-eluting beads: doxorubicin tissue concentration and distribution in patient liver explants. J. Hepatol. 55 (6), 1332\u20131338 (2011).","journal-title":"J. Hepatol."},{"issue":"1","key":"65418_CR32","doi-asserted-by":"publisher","first-page":"45252","DOI":"10.1038\/s41598-025-29214-9","volume":"15","author":"M Lee","year":"2025","unstructured":"Lee, M. et al. Modeling the metastatic tumor microenvironment: a co-culture platform of lung cancer and blood vessel organoids for drug evaluation. Sci. Rep. 15 (1), 45252 (2025).","journal-title":"Sci. Rep."},{"issue":"12","key":"65418_CR33","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1038\/nm.4438","volume":"23","author":"L Broutier","year":"2017","unstructured":"Broutier, L. et al. Human primary liver cancer\u2013derived organoid cultures for disease modeling and drug screening. Nat. Med. 23 (12), 1424\u20131435 (2017).","journal-title":"Nat. Med."},{"issue":"4","key":"65418_CR34","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.cell.2015.03.053","volume":"161","author":"M van de Wetering","year":"2015","unstructured":"van de Wetering, M. et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell 161 (4), 933\u2013945 (2015).","journal-title":"Cell"},{"issue":"1\u20132","key":"65418_CR35","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.cell.2014.12.021","volume":"160","author":"SF Boj","year":"2015","unstructured":"Boj, S. F. et al. Organoid models of human and mouse ductal pancreatic cancer. Cell 160 (1\u20132), 324\u2013338 (2015).","journal-title":"Cell"},{"issue":"5","key":"65418_CR36","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1158\/2159-8290.CD-16-1154","volume":"7","author":"C Pauli","year":"2017","unstructured":"Pauli, C. et al. Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine. Cancer Discov. 7 (5), 462\u2013477 (2017).","journal-title":"Cancer Discov"},{"key":"65418_CR37","doi-asserted-by":"crossref","unstructured":"Lo Re, O. et al. Establishment of Patient-Derived Organoids from Hepatocellular Carcinoma: Preliminary Data on Yield, Histopathological Concordance, and Methodological Challenges. Cells, 15(2). (2026).","DOI":"10.3390\/cells15020125"},{"issue":"7","key":"65418_CR38","doi-asserted-by":"publisher","first-page":"101426","DOI":"10.1016\/j.jhepr.2025.101426","volume":"7","author":"AM Wong","year":"2025","unstructured":"Wong, A. M. et al. Patient-derived organoids inform pharmacogenomic vulnerabilities in liver cancer. JHEP Rep. 7 (7), 101426 (2025).","journal-title":"JHEP Rep."},{"issue":"1","key":"65418_CR39","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1186\/s12967-024-05230-7","volume":"22","author":"AM El-Derby","year":"2024","unstructured":"El-Derby, A. M. et al. Plasma-derived extracellular matrix for xenofree and cost-effective organoid modeling for hepatocellular carcinoma. J. Transl Med. 22 (1), 487 (2024).","journal-title":"J. Transl Med."},{"key":"65418_CR40","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.canlet.2018.03.031","volume":"425","author":"K Koikawa","year":"2018","unstructured":"Koikawa, K. et al. Basement membrane destruction by pancreatic stellate cells leads to local invasion in pancreatic ductal adenocarcinoma. Cancer Lett. 425, 65\u201377 (2018).","journal-title":"Cancer Lett."},{"issue":"1","key":"65418_CR41","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1186\/s12885-018-4238-4","volume":"18","author":"S Tsai","year":"2018","unstructured":"Tsai, S. et al. Development of primary human pancreatic cancer organoids, matched stromal and immune cells and 3D tumor microenvironment models. BMC Cancer. 18 (1), 335 (2018).","journal-title":"BMC Cancer"},{"issue":"7","key":"65418_CR42","doi-asserted-by":"publisher","first-page":"639","DOI":"10.3390\/ph14070639","volume":"14","author":"A Fohlen","year":"2021","unstructured":"Fohlen, A. et al. Anticancer Drugs for Intra-Arterial Treatment of Colorectal Cancer Liver Metastases: In-Vitro Screening after Short Exposure Time. Pharmaceuticals 14 (7), 639 (2021).","journal-title":"Pharmaceuticals"},{"key":"65418_CR43","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jcis.2020.07.092","volume":"581","author":"D Matyszewska","year":"2021","unstructured":"Matyszewska, D., Nazaruk, E. & Campbell, R. A. Interactions of anticancer drugs doxorubicin and idarubicin with lipid monolayers: New insight into the composition, structure and morphology. J. Colloid Interface Sci. 581, 403\u2013416 (2021).","journal-title":"J. Colloid Interface Sci."},{"key":"65418_CR44","doi-asserted-by":"publisher","first-page":"101143","DOI":"10.1016\/j.jddst.2019.101143","volume":"53","author":"E Ahnfelt","year":"2019","unstructured":"Ahnfelt, E. et al. Lipiodol-based emulsions used for transarterial chemoembolization and drug delivery: Effects of composition on stability and product quality. J. Drug Deliv. Sci. Technol. 53, 101143 (2019).","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"65418_CR45","doi-asserted-by":"crossref","unstructured":"Pohlberger, R. F. et al. From Patient Liver Tissue to Organoids: Establishment of a Translational Platform Using Healthy, Steatotic, and Cirrhotic Tissue Sources. Cells, 15(5). (2026).","DOI":"10.3390\/cells15050432"},{"issue":"6","key":"65418_CR46","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1016\/j.cell.2018.11.013","volume":"175","author":"H Hu","year":"2018","unstructured":"Hu, H. et al. Long-Term Expansion of Functional Mouse and Human Hepatocytes as 3D Organoids. Cell 175 (6), 1591\u20131606e19 (2018).","journal-title":"Cell"},{"issue":"Suppl","key":"65418_CR47","doi-asserted-by":"publisher","first-page":"S327","DOI":"10.3350\/cmh.2024.1040","volume":"31","author":"Y Kim","year":"2025","unstructured":"Kim, Y. et al. Liver organoids: Current advances and future applications for hepatology. Clin. Mol. Hepatol. 31 (Suppl), S327\u2013S348 (2025).","journal-title":"Clin. Mol. Hepatol."},{"issue":"7","key":"65418_CR48","doi-asserted-by":"publisher","first-page":"987","DOI":"10.3390\/cancers11070987","volume":"11","author":"B Guiu","year":"2019","unstructured":"Guiu, B. et al. Transarterial Chemoembolization of Hepatocellular Carcinoma with Idarubicin-Loaded Tandem Drug-Eluting Embolics. Cancers 11 (7), 987 (2019).","journal-title":"Cancers"},{"key":"65418_CR49","doi-asserted-by":"crossref","unstructured":"Balgoma, D. et al. Anthracyclins Increase PUFAs: Potential Implications in ER Stress and Cell Death. Cells, 10(5). (2021).","DOI":"10.3390\/cells10051163"},{"key":"65418_CR50","doi-asserted-by":"crossref","unstructured":"Malik, A. et al. Doxorubicin\u2013induced cardiomyopathy is mitigated by empagliflozin via the modulation of endoplasmic reticulum stress pathways. Mol. Med. Rep., 29(5). (2024).","DOI":"10.3892\/mmr.2024.13198"},{"key":"65418_CR51","doi-asserted-by":"publisher","first-page":"101846","DOI":"10.1016\/j.molmet.2023.101846","volume":"79","author":"M Kopsida","year":"2024","unstructured":"Kopsida, M. et al. Inhibiting the endoplasmic reticulum stress response enhances the effect of doxorubicin by altering the lipid metabolism of liver cancer cells. Mol. Metab. 79, 101846 (2024).","journal-title":"Mol. Metab."},{"key":"65418_CR52","doi-asserted-by":"publisher","first-page":"101329","DOI":"10.1016\/j.neo.2026.101329","volume":"79","author":"J Khaled","year":"2026","unstructured":"Khaled, J. et al. Inhibition of PERK signaling suppresses tumor progression and blocks GP73-GRP78-dependent stromal activation in hepatocellular carcinoma. Neoplasia 79, 101329 (2026).","journal-title":"Neoplasia"},{"issue":"3","key":"65418_CR53","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9","volume":"182","author":"T Scholzen","year":"2000","unstructured":"Scholzen, T. & Gerdes, J. The Ki-67 protein: from the known and the unknown. J. Cell. Physiol. 182 (3), 311\u2013322 (2000).","journal-title":"J. Cell. Physiol."},{"issue":"6","key":"65418_CR54","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/sj.onc.1200886","volume":"14","author":"Z Kelman","year":"1997","unstructured":"Kelman, Z. PCNA: structure, functions and interactions. Oncogene 14 (6), 629\u2013640 (1997).","journal-title":"Oncogene"},{"issue":"2","key":"65418_CR55","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1124\/pr.56.2.6","volume":"56","author":"G Minotti","year":"2004","unstructured":"Minotti, G. et al. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 56 (2), 185\u2013229 (2004).","journal-title":"Pharmacol. Rev."},{"issue":"5","key":"65418_CR56","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/nrc2607","volume":"9","author":"JL Nitiss","year":"2009","unstructured":"Nitiss, J. L. Targeting DNA topoisomerase II in cancer chemotherapy. Nat. Rev. Cancer. 9 (5), 338\u2013350 (2009).","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"65418_CR57","doi-asserted-by":"publisher","first-page":"12967","DOI":"10.1080\/21655979.2021.2012069","volume":"12","author":"Y Dong","year":"2021","unstructured":"Dong, Y. et al. Type IIA topoisomerase (TOP2A) triggers epithelial-mesenchymal transition and facilitates HCC progression by regulating Snail expression. Bioengineered 12 (2), 12967\u201312979 (2021).","journal-title":"Bioengineered"},{"issue":"1","key":"65418_CR58","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12935-021-02439-0","volume":"22","author":"J Meng","year":"2022","unstructured":"Meng, J. et al. Study on the expression of TOP2A in hepatocellular carcinoma and its relationship with patient prognosis. Cancer Cell. Int. 22 (1), 29 (2022).","journal-title":"Cancer Cell. Int."},{"key":"65418_CR59","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.cancergen.2024.10.005","volume":"288-289","author":"G Liu","year":"2024","unstructured":"Liu, G. et al. Elucidating the prognostic and therapeutic significance of TOP2A in various malignancies. Cancer Genet. 288-289, 68\u201381 (2024).","journal-title":"Cancer Genet."},{"key":"65418_CR60","doi-asserted-by":"publisher","first-page":"641980","DOI":"10.3389\/fonc.2021.641980","volume":"11","author":"M Verduin","year":"2021","unstructured":"Verduin, M. et al. Patient-Derived Cancer Organoids as Predictors of Treatment Response. Front. Oncol. 11, 641980 (2021).","journal-title":"Front. Oncol."},{"issue":"7","key":"65418_CR61","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/s41568-018-0007-6","volume":"18","author":"J Drost","year":"2018","unstructured":"Drost, J. & Clevers, H. Organoids in cancer research. Nat. Rev. Cancer. 18 (7), 407\u2013418 (2018).","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"65418_CR62","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s41563-021-01057-5","volume":"21","author":"BL LeSavage","year":"2022","unstructured":"LeSavage, B. L. et al. Next-generation cancer organoids. Nat. Mater. 21 (2), 143\u2013159 (2022).","journal-title":"Nat. Mater."},{"issue":"7","key":"65418_CR63","doi-asserted-by":"publisher","first-page":"606","DOI":"10.3348\/kjr.2023.0385","volume":"24","author":"Y Cho","year":"2023","unstructured":"Cho, Y. et al. Transarterial Chemoembolization for Hepatocellular Carcinoma: 2023 Expert Consensus-Based Practical Recommendations of the Korean Liver Cancer Association. Korean J. Radiol. 24 (7), 606\u2013625 (2023).","journal-title":"Korean J. Radiol."},{"key":"65418_CR64","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.trsl.2022.08.003","volume":"250","author":"E Podaza","year":"2022","unstructured":"Podaza, E. et al. Next generation patient derived tumor organoids. Transl Res. 250, 84\u201397 (2022).","journal-title":"Transl Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-65418-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-65418-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-65418-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T10:03:17Z","timestamp":1785837797000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-65418-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["65418"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-65418-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,4]]},"assertion":[{"value":"27 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"24015"}}